FDA Grants Priority Review for Genzyme’s Cerdelga

US regulatory body, the Food and Drug Administration (FDA), have announced that they will be undertaking an accelerated a review of Sanofi’s Genzyme unit’s Gaucher disease drug, Cerdelga (eliglustat), having granted a six-month priority review for the application. Gaucher disease is a genetic disorder where lipids build up in cells and certain organs, causing problems

Continue Reading